Stem Cell Therapeutics (SCT; Calgary, Alberta) at this year's Stroke meeting reported favorable results from its Beta-hCG + Erythropoietin in Acute Stroke (BETAS) Phase IIa, open label, safety trial conducted at the University of California, Irvine and Hoag Presbyterian Memorial Hospital (Newport Beach, California).